Cetuximab
Monoclonal antibody targets EGFR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | ERBITUX | — | 2006-03-01 – 2021-09-24 | fda.gov ↗ |
| Approved | EU (EMA) | Erbitux | — | 2004-06-29 | europa.eu ↗ |
| Approved | US (FDA) | ERBITUX | — | 2004-02-12 | fda.gov ↗ |
Trials 772 · started per year
Also used as a comparator or background therapy in 251 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07318389 Background | Jun 2026 → Nov 2027 expected | colorectal cancer | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06011772 Background | Dec 2023 → Feb 2026 overdue | colorectal cancer | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 152 trials | ||||||
| Phase 1 | NCT07672483 Background | Jul 2026 → Jan 2028 expected | neoplastic disease or syndrome | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07217028 Background | Apr 2026 → Apr 2029 expected | head and neck squamous cell carcinoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07318805 Background | Dec 2025 → Apr 2029 expected | colorectal adenocarcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT07300150 Background | Nov 2025 → Oct 2028 expected | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | PAQ Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07204340 Background | Sep 2025 → Dec 2031 expected | — | Treeline Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06912087 Background | Sep 2025 → Jun 2027 expected | head and neck neoplasm, metastatic neoplasm, squamous cell carcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 1 | NCT06865664 Background | Sep 2025 → Dec 2027 expected | rhabdomyosarcoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT07030959 Background | Jun 2025 → Dec 2029 expected | cancer | Chugai Pharmaceutical | Recruiting | No outcome recorded |
| Phase 1 | NCT06980454 Comparator | Jun → Dec 2025 overdue | colorectal cancer | Shanghai Henlius Biotech | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06818812 Background | Mar 2025 → Mar 2027 expected | cancer | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06358430 Background | Dec 2024 → Jan 2029 expected | colorectal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06607185 Background | Oct 2024 → Jan 2030 expected | colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06586515 Background | Sep 2024 → Mar 2029 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05985954 Background | Jan 2024 → Mar 2028 expected | colorectal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06179160 Background | Jan 2024 → Jan 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT05722327 Background | Dec 2023 → Sep 2027 expected | colon carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05376202 Background | Mar 2022 → May 2023 | squamous cell carcinoma of penis | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT04638036 Background | Nov 2020 → Jan 2022 | rectal cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT03774680 Comparator | Feb 2020 | colon carcinoma | Al-Azhar University | Unknown | No outcome recorded |
| Phase 1 | NCT04091867 Background | Jan 2020 → May 2021 | head and neck squamous cell carcinoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT03667482 Background | Sep 2018 → Jul 2024 | head and neck squamous cell carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03491709 Comparator | Jul 2018 → Sep 2019 | colorectal cancer | Dragonboat Biopharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03356158 Comparator | Nov 2017 → Oct 2018 | colorectal cancer | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03881787 Comparator | Apr 2017 → Aug 2019 | — | Dragonboat Biopharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02555644 Background | Feb 2016 → Jan 2019 | head and neck neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02675946 Background | Feb 2016 → Mar 2023 | digestive system cancer | Curegenix Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT02350712 Background | Dec 2014 → Mar 2016 | head and neck squamous cell carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02282371 Background | Oct 2014 → Oct 2021 | head and neck squamous cell carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02124148 Background | Jun 2014 → Feb 2020 | breast cancer, colorectal neoplasm, metastatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01935921 Background | Apr 2013 → Oct 2016 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oropharynx squamous cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01787500 Background | Feb 2013 → Jan 2022 | colorectal cancer, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01758731 Background | Oct 2012 → Dec 2016 | head and neck squamous cell carcinoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT01540682 Background | Feb 2012 → Nov 2015 | head and neck squamous cell carcinoma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01472016 Background | Oct 2011 → Apr 2017 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01254617 Background | Feb 2011 → Jan 2014 | colon carcinoma, hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, major salivary gland carcinoma +8 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01294826 Background | Feb 2011 → May 2015 | colon adenocarcinoma, rectum adenocarcinoma | Swedish Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01360827 Background | Aug 2010 → Apr 2011 | head and neck squamous cell carcinoma | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 1 | NCT01031212 Background | Jan 2010 → Jun 2012 | neoplasm | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 1 | NCT02845999 Background | Nov 2009 → Jan 2013 | digestive system cancer | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 1 | NCT01046266 Comparator | Nov 2009 → Jun 2012 | head and neck squamous cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01285037 Background | Sep 2009 → Jul 2017 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00882583 Background | Jul 2009 → Feb 2016 | head and neck cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1 | NCT00719199 Background | Jan 2009 → Apr 2011 | colorectal cancer | EMD Serono | Terminated | No outcome recorded |
| Phase 1 | NCT00906360 Background | Jul 2008 → Sep 2012 | hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, metastatic squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma +5 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00497497 Background | Oct 2007 → Sep 2010 | colorectal cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00540943 Background | Jul 2007 → May 2010 | colorectal cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00388427 Background | Jun 2007 → Jul 2009 | cancer | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1 | NCT00402545 Background | Jan 2007 → Jul 2009 | head and neck squamous cell carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00671372 Background | Jul 2006 → Mar 2012 | colorectal cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00207051 Background | Jan 2006 → Dec 2008 | colorectal cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00110357 Comparator | Aug 2005 → Mar 2008 | refractory malignant neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00502567 Background | Jan 2005 → Nov 2007 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1/236 trials | ||||||
| Phase 1/2 | NCT07678593 Background | Sep 2026 → Nov 2027 expected | pancreatic ductal adenocarcinoma | Genfleet Therapeutics (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07683403 Comparator | Jun 2026 → Jun 2028 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07551778 Background | May 2026 → Apr 2028 expected | colorectal cancer, non-small cell lung carcinoma | BOE Technology Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07411599 Background | Apr 2026 → Nov 2028 expected | colorectal cancer, peritoneal carcinomatosis | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07020221 Background | Jun 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Verastem, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07204574 Background | May → Dec 2025 overdue | — | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06771622 Background | Mar 2025 → Jan 2028 expected | — | FBD Biologics Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06445062 Background | May 2024 → May 2027 expected | colorectal cancer, pancreatic ductal adenocarcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06385925 Background | Apr 2024 → Oct 2026 expected | cancer | Tyligand Pharmaceuticals (Suzhou) Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06776757 Background | Dec 2023 → Jun 2025 overdue | colorectal cancer | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05786924 Background | Apr 2023 → Jun 2028 expected | colorectal carcinoma, histiocytic and dendritic cell neoplasm, histiocytosis, metastatic malignant neoplasm in the brain +2 | Servier | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02826837 Background | Sep 2022 → Feb 2024 | colorectal cancer | Taiwan Leader Biotech Corp. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04717375 Background | Apr 2021 → Jul 2025 | cancer | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT04616196 Background | Oct 2020 → Mar 2023 | colorectal cancer, head and neck squamous cell carcinoma | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT04165031 Background | Nov 2019 → Oct 2020 | colorectal cancer, non-small cell lung carcinoma | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1/2 | NCT03693612 Comparator | Nov 2018 → Jun 2021 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT03009058 Background | May → Aug 2017 | metastatic malignant neoplasm | Immodulon Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 1/2 | NCT03109158 Background | Mar 2017 → Mar 2019 | head and neck squamous cell carcinoma | NanoCarrier Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02855086 Background | Oct → Nov 2016 | brain neoplasm, malignant glioma | Eben Rosenthal | Terminated | No outcome recorded |
| Phase 1/2 | NCT02671435 Background | Feb 2016 → Oct 2021 overdue | cancer | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01332266 Comparator | Sep 2011 → Jan 2016 | head and neck squamous cell carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01283334 Background | Jan 2011 → Nov 2013 | head and neck cancer | Emory University | Completed | No outcome recorded |
| Phase 1/2 | NCT01178411 Background | Aug 2010 → Jan 2019 | cancer | ArQule, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01075048 Background | Jan 2010 → Oct 2012 | colorectal cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/2 | NCT00908024 Background | Oct 2009 → Dec 2012 | colorectal cancer, head and neck cancer, metastatic neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/2 | NCT01008475 Background | Oct 2009 → Apr 2015 | colorectal cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/2 | NCT01009346 Background | Oct 2009 → Mar 2011 | head and neck cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1/2 | NCT00954512 Background | Sep 2009 → Jun 2011 | neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT00851877 Background | Mar 2009 → Oct 2013 | head and neck cancer | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00705016 Background | Oct 2008 → Sep 2011 | squamous cell carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/2 | NCT00594984 Comparator | May 2008 → Dec 2012 | colorectal cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT00551421 Background | Oct 2007 → Nov 2010 | colon adenocarcinoma, rectum adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00545545 Background | Oct 2007 → Dec 2009 | colorectal carcinoma | HiberCell, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00522665 Comparator | Aug 2007 → May 2011 | colorectal cancer | Hoosier Cancer Research Network | Completed | No outcome recorded |
| Phase 1/2 | NCT00425425 Background | Jul 2006 → May 2010 | esophageal cancer | Technical University of Munich | Unknown | No outcome recorded |
| Phase 1/2 | NCT00361244 Background | Jul 2006 → Oct 2007 | colorectal carcinoma | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2107 trials | ||||||
| Phase 2 | NCT07715734 Background | Sep 2026 → Mar 2031 expected | skin squamous cell carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07604909 Background | May 2026 → Sep 2027 expected | colorectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07415031 Background | May 2026 → Feb 2028 expected | cancer | Mirati Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07474727 Background | Apr 2026 → Sep 2027 expected | colorectal cancer | Multitude Therapeutics Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07042295 Comparator | Mar 2026 → Feb 2029 expected | skin squamous cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Show all 107 trials opens the full record — a long page | ||||||
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07509398 Background | Apr 2026 → Dec 2027 expected | colorectal cancer | Shanghai 10th People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03258554 Comparator | Apr 2018 → Sep 2022 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT03031444 Comparator | Jan 2016 → Dec 2020 | colorectal cancer, metastatic neoplasm | Peking University Cancer Hospital & Institute | Completed | No outcome recorded |
| Phase 344 trials | ||||||
| Phase 3 | NCT07702032 Comparator | Jul 2026 → Jul 2029 expected | colorectal cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT07595276 Comparator | Jun 2026 → Oct 2029 expected | colorectal cancer | Taizhou Mabtech Pharmaceutical Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07309289 Comparator | Jul 2025 → Mar 2029 expected | colorectal cancer | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06706401 Background | Feb 2025 → Jan 2029 expected | hypopharynx cancer, larynx cancer, oropharynx cancer | Centre Leon Berard | Recruiting | No outcome recorded |
| Phase 3 | NCT06750094 Comparator | Dec 2024 → Dec 2027 expected | colorectal neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06662786 Comparator | Oct 2024 → Dec 2028 expected | colorectal cancer | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06064877 Background | Jan 2024 → Aug 2027 expected | head and neck squamous cell carcinoma | AVEO Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05930938 Background | Dec 2023 → Sep 2024 | head and neck squamous cell carcinoma | Groupe Oncologie Radiotherapie Tete et Cou | Terminated | No outcome recorded |
| Phase 3 | NCT06008119 Comparator | Oct 2023 → Dec 2026 expected | colorectal cancer | Shanghai Kechow Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05863195 Background | Oct 2023 → Jun 2029 expected | colorectal carcinoma, metastatic malignant neoplasm | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 3 | NCT05751512 Comparator | Mar 2023 → Aug 2025 | head and neck squamous cell carcinoma | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT05652894 Comparator | Feb 2023 → Jun 2026 overdue | colorectal cancer | Taizhou Hanzhong Biomedical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05253651 Comparator | Oct 2022 → Dec 2027 expected | colorectal neoplasm | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT05239741 Comparator | Apr 2022 → Sep 2028 expected | colorectal cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04262635 Comparator | Sep 2021 → Dec 2022 | colorectal cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT05074966 Background | Sep 2021 → Jun 2024 | colorectal cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT04776655 Comparator | Apr 2021 → May 2025 overdue | colorectal cancer | Azienda USL Reggio Emilia - IRCCS | Recruiting | No outcome recorded |
| Phase 3 | NCT04008030 Comparator | Aug 2019 → Aug 2024 overdue | colorectal cancer | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03769506 Comparator | May 2019 → Dec 2025 overdue | head and neck squamous cell carcinoma | Rakuten Medical, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03529279 Comparator | Jun 2018 → Jun 2026 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03386838 Comparator | Mar → Apr 2018 | head and neck cancer | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 3 | NCT03342352 Comparator | Dec 2017 → Apr 2018 | head and neck cancer | Incyte Corporation | Withdrawn | No outcome recorded |
| Phase 3 | NCT03358472 Comparator | Dec 2017 → Jul 2018 | head and neck squamous cell carcinoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02236936 Background | Feb 2017 → Jul 2019 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Study Group of Medical Tumour Therapy (AGMT) | Terminated | No outcome recorded |
| Phase 3 | NCT02928224 Background | Oct 2016 → Feb 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02741570 Comparator | Oct 2016 → May 2021 | head and neck cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02563002 Comparator | Nov 2015 → Feb 2021 | colorectal carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02551159 Comparator | Oct 2015 → Jul 2020 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02369874 Comparator | Sep 2015 → Sep 2018 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02358031 Comparator | Mar 2015 → Feb 2019 | head and neck cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02314182 Background | Nov 2014 → Feb 2018 | rectum adenocarcinoma | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 3 | NCT02252042 Comparator | Nov 2014 → May 2017 | head and neck squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02105636 Comparator | May 2014 → Nov 2015 | head and neck squamous cell carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01855451 Comparator | Jun 2013 → Apr 2020 | oropharynx squamous cell carcinoma | Trans Tasman Radiation Oncology Group | Unknown | No outcome recorded |
| Phase 3 | NCT01338558 Comparator | Jun 2011 → May 2015 | colorectal cancer | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 3 | NCT01302834 Comparator | Jun 2011 → Jul 2018 | oropharyngeal carcinoma, precancerous condition | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT01309126 Comparator | Apr 2011 → Feb 2017 | colorectal cancer | HiberCell, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01001377 Comparator | Feb 2010 → Feb 2013 | colorectal cancer | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00820755 Comparator | Jan 2009 → Dec 2011 | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00640471 Comparator | May 2008 → Sep 2011 | colorectal cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00609284 Background | Feb 2008 → Mar 2018 | head and neck squamous cell carcinoma | Groupe Oncologie Radiotherapie Tete et Cou | Completed | No outcome recorded |
| Phase 3 | NCT00433927 Comparator | Jan 2007 → Apr 2014 | colorectal cancer, metastatic malignant neoplasm | PD Dr. med. Volker Heinemann | Unknown | No outcome recorded |
| Phase 3 | NCT00112294 Comparator | Dec 2004 → Apr 2007 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00004227 Comparator | Apr 1999 → Mar 2007 | head and neck cancer | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05894694 Background | Sep 2023 → Dec 2025 overdue | colorectal cancer | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT02015650 Comparator | Apr 2014 → Apr 2016 | head and neck squamous cell carcinoma | Medical University Innsbruck | Terminated | No outcome recorded |
| Phase 4 | NCT01553032 Comparator | Jun 2011 → May 2017 | head and neck cancer | University of Heidelberg Medical Center | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT04131803 Background | Oct 2021 → Nov 2022 | colorectal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT01834014 Comparator | May 2013 → Mar 2017 | metastasis from malignant tumor of colon | EPS Corporation | Completed | No outcome recorded |
| — | NCT01326468 Background | Dec 2011 → Dec 2016 | head and neck cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Withdrawn | No outcome recorded |
| — | NCT01317433 Background | Dec 2010 → Oct 2016 | colorectal cancer, toxic dermatosis | Institut Cancerologie de l'Ouest | Terminated | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-04-08 | Pfizer | U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy pfizer.com ↗ |
| 2019-12-18 | Pfizer | U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy pfizer.com ↗ |
| 2019-09-29 | Pfizer | Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer pfizer.com ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 1,031 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cetuximab | “Investigator's choice of standard first-line systemic therapy for initially unresectable colorectal cancer, including chemotherapy (e.g., FOLFOX, FOLFIRI, CAPOX) with or...” NCT07509398 ↗1005“Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil +...” NCT05978349 ↗ “Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the...” NCT01178411 ↗ “During cycle I (chemoradiation), gemcitabine (200 mg/m2) and cetuximab 400mg/m2 initial dose followed by 250mg/m2 IV weekly will be given with continuous infusion 5-FU (200...” NCT00424827 ↗ “The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third...” NCT03077243 ↗ “Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux)...” NCT01892527 ↗ “A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux®...” NCT06980454 ↗ “Drug: cetuximab 400 mg/m2 for the first dose, then 250 mg/sqm, intravenous infusion, repeated weekly; or Cetuximab 500 mg/ sqm, intravenous infusion, D1, repeated every 2 weeks.” NCT05652894 ↗ “Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.” NCT04508829 ↗ “First-line standard systemic therapies in cohort A include: FOLFOX/FOLIRI/XELOX+ bevacizumab, FOLFOX/FOLIRI/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only).” NCT06841159 ↗ “* Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.” NCT01923987 ↗ “Subjects will receive a single intra-arterial dose of Cetuximab (200 mg/m\^2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).” NCT01884740 ↗ “The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes” NCT01102231 ↗ “Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.” NCT01307878 ↗ “The aim of the trial is to study the efficacy and safety of Cetuximab re-challenge for Chinese Patients with RAS/BRAF wild-type Metastatic Colorectal Cancer.” NCT04224415 ↗ “durvalumab 20 mg/kg q4w plus tremelimumab 1 mg/kg q4w × 4, then durvalumab 10 mg/kg q2w), or SoC (cetuximab, a taxane, methotrexate, or a fluoropyrimidine).” PMID 32294530 ↗ Apr 2020 “C225 = Cetuximab: 400 mg/m2 IV will be given as the initial OR loading dose in week 1 and then 250 mg/m2 IV weekly will be given for 8 weeks (weeks 2-9).” NCT00343083 ↗ “INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)” NCT06477692 ↗ “Here, we evaluate EGFR FISH as a predictive marker in NSCLC patients receiving the EGFR monoclonal antibody inhibitor cetuximab plus chemotherapy.” PMID 18612151 ↗ Jul 2008 “Cetuximab 400 mg/m², intravenous infusion, first infusion over \>2 hours, then 250 mg/m² intravenous infusion over ≥60 minutes, repeated weekly” NCT07604909 ↗ “Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer” NCT00248287 ↗ “Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.” NCT06199232 ↗ “Cetuximab is also a drug approved by the FDA for the treatment of cancer of the colon and rectum, as well as cancer of the head and neck.” NCT00183898 ↗ “This is a Phase Ib/II clinical study aimed at exploring the safety and efficacy of Regimen A (GFH375 in combination with Cetuximab)” NCT07259590 ↗ “NT219 Injection Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer” NCT04474470 ↗ “Cetuximab treatment will be started (day 0) with 400 mg/m2 followed by two doses of 250 mg/m2 (once weekly on day 7 and 14).” NCT01760811 ↗ “mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment” NCT03135652 ↗ “For left-sided colon and rectal cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Cetuximab.” NCT05797467 ↗ “Anti-EGFR treatment with either Panitumumab (6 mg/kg IV over 60 minutes, Day 1) or Cetuximab (500 mg/m² IV, Day 1).” NCT06575127 ↗ “Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance.” NCT03017807 ↗ “TSN1611 BID, Cetuximab will be administered via intravenous infusion at a dose of 500 mg/m² every 2 weeks.” NCT06385925 ↗ “chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion” NCT03067610 ↗ “Patients will start with induction chemotherapy of carboplatin, paclitaxel and cetuximab for 6 weeks” NCT06984861 ↗ “Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.” NCT04136600 ↗ “Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab” NCT05409417 ↗ “Standard second-line systemic therapy: (XELOX/FOLFOX or XELIRI/FOLFIRI ± bevacizumab/cetuximab)” NCT07079462 ↗ “Cetuximab will be administered via intravenous infusion at a dose of 500 mg/m² every 2 weeks.” NCT07554859 ↗ “PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles.” NCT06725368 ↗ “Cetuximab with or without Irinotecan (for patients not previously treated with cetuximab).” NCT07353268 ↗ “K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option).” NCT01366118 ↗ “Cetuximab has shown the potentialisation on the efficacy of cisplatine and irinotecan.” NCT00518193 ↗ “combination of cetuximab/bevacizumab and other targeted agents depends on the patient.” NCT05797883 ↗ “Cetuximab Day 1, 8, 15, Q3W, 400 mg/m2 initial dose; Afterwards, 250 mg/m2 per week” NCT06081582 ↗ “combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.” NCT03567629 ↗ “Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice.” NCT06207656 ↗ “Drug: Cetuximab 500mg/m\^2, intravenous infusion, d1, 14 days per cycle.” NCT07309289 ↗ “and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter” NCT01744340 ↗ “FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only)” NCT06525428 ↗ “Standard therapy：FOLFOX/FOLFIRI/XELOX/ mXELIRI±bevacizumab/cetuximab” NCT06856187 ↗ “first-line regimen (FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab)” NCT05894694 ↗ “Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly )” NCT01133678 ↗ “cetuximab 500mg/m2 intravenous infusion over 2 hours day 1” NCT04131803 ↗ “Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly” NCT06521866 ↗ “Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min” NCT03174405 ↗ “K-ras native: Cetuximab. K-ras mutated: Bevacizumab” NCT01453257 ↗ “Neoadjuvant Encorafenib, Binimetinib and Cetuximab” NCT05510895 ↗ “cetuximab N01 500 mg/m² IV infusion on Day 1, q2w” NCT07581626 ↗ “docetaxel, cetuximab, methotrexate, paclitaxel” NCT03769506 ↗ “NUC-3373 + oxaliplatin + cetuximab/panitumumab” NCT03428958 ↗ “VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)” NCT05540951 ↗ “± Cetuximab 500mg/m2, repeating every 2 weeks” NCT03485027 ↗ “cetuximab（monoclonal antibody against EGFR）” NCT05143099 ↗ “either avelumab, trastuzumab or cetuximab” NCT05069935 ↗ “Cetuximab: 500mg/m2,day1, every 2 weeks.” NCT05468177 ↗ “cetuximab 250mg/m2 or bevacizumab 5mg/kg” NCT03022734 ↗ “cetuximab (500 mg/m2, iv drop, d1)” NCT07515963 ↗ “Drug: Cetuximab Drug: Trastuzumab” NCT03768375 ↗ “Cetuximab 500mg/sq.m (d.i.v.)；” NCT04160416 ↗ “INTERVENTION: SSIA Cetuximab.” PMID 27849340 ↗ Nov 2016 “Cetuximab Injection [Erbitux]” NCT04984369 ↗ “carboplatin and cetuximab” NCT03529279 ↗ “Erbitux® (Cetuximab)” NCT06309043 ↗ “Cetuximab (Erbitux)” NCT01181401 ↗ “9. EGFR: Cetuximab” NCT02101385 ↗ “* cetuximab” NCT03070366 ↗ “* Cetuximab” NCT03251612 ↗ “Cetuximab” NCT02063529 ↗ “Cetuximab” NCT03647423 ↗ “Cetuximab” NCT02142036 ↗ “Cetuximab” NCT06496178 ↗ “cetuximab” NCT04009681 ↗ “Cetuximab” NCT01703910 ↗ |
| Known as | C225 | “A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor...” NCT00079066 ↗16“A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic...” NCT00056030 ↗ “A Phase II Trial of Cetuximab (c225) as Therapy for Recurrent Non-Small Cell Lung Cancer in Patients Who Have Received Prior Therapy With Tyrosine Kinase Inhibitor Directed...” NCT00694603 ↗ “Cetuximab (C225) and Radiation in Elderly and /or Poor Performance Status Patients With Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study to Evaluate Survival and Toxicity” NCT00124618 ↗ “This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.” NCT00700440 ↗ “A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer” NCT00104910 ↗ “C225 = Cetuximab: 400 mg/m2 IV will be given as the initial OR loading dose in week 1 and then 250 mg/m2 IV weekly will be given for 8 weeks (weeks 2-9).” NCT00343083 ↗ “Cetuximab (C-225), a Chimeric Monoclonal Antibody Against the Epidermal Growth Factor Receptor (EGFR)” NCT00820417 ↗ “Cetuximab (C225) is a human/murine chimeric monoclonal antibody directed to the EGFR binding site.” NCT00536614 ↗ “cetuximab (C225), an antibody that inhibits epidermal growth factor receptor (EGFR) activity” PMID 21329967 ↗ Feb 2011 “Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.” NCT01758731 ↗ “A Phase II Study Of Cetuximab (C225) In Combination With Chemoradiation” NCT00081302 ↗ “cetuximab (C225, Erbitux) in combination with carboplatin” PMID 18191993 ↗ Jan 2008 “Cetuximab (Erbitux, C225)” NCT00388427 ↗ “Cetuximab or c225” NCT05959356 ↗ “Cetuximab (C225)” NCT00265850 ↗ |
| Known as | Cetux | “The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus” PMID 39313594 ↗ Sep 2024 |
| Known as | cetuxiamb | “EGFR antibodies panitumumad and cetuxiamb in case of KRAS wild-type tumors.” NCT02314182 ↗ |
| Known as | Cetuximab (C225, Erbitux by Merck) | “Cetuximab (C225, Erbitux by Merck)” NCT00422773 ↗ |
| Known as | Cetuximab (C225, Erbitux) | “Cetuximab (C225, Erbitux)” NCT00580073 ↗ |
| Known as | Cetuximab (Erbitux) | “Cetuximab (Erbitux)” NCT01192087 ↗ |
| Known as | Cetuximab Beta | “Camrelizumab 200 mg (Day 1) intravenous infusion (IV), Cetuximab Beta 400 mg/m² (Day 1) IV, followed by 250 mg/m² IV weekly, with a 21-day cycle for 2 cycles; followed by...” NCT07432087 ↗ |
| Known as | Cetuximab Beta Injection | “Cetuximab Beta Injection 500mg/㎡ IV, q14d” NCT07294261 ↗ |
| Known as | Cetuximab or c225 | “Cetuximab or c225” NCT05959356 ↗ |
| Known as | cetuximab β | “Despite this established approach, cetuximab β (CMAB009), as a modified antibody of cetuximab, prospectively selected for dual RAS/BRAF wild-type patients, has not yet been...” PMID 40328753 ↗ May 2025 |
| Known as | Cetuximab(C225, Erbitux, Merck KGaA) | “Cetuximab(C225, Erbitux®, Merck KGaA)” NCT00153998 ↗ |
| Known as | CMAB009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03206151 ↗ |
| Known as | CTX | “GBM often has a high expression EFGR (Epidermal Growth Factor Receptor) which is blocked by Cetuximab (CTX).” NCT02861898 ↗3“an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the concurrent therapy” NCT00343083 ↗ “intracranial superselective intra-arterial infusion of Cetuximab (CTX), at a dose of 250mg/m2” NCT02800486 ↗ “cetuximab (CTX) or nimotuzumab (NTZ)” NCT04508816 ↗ |
| Known as | Erbitux | “the rationale of the combination of lenalidomide with a therapeutic IgG1 antibody such as cetuximab (Erbitux®) is based on the fact that several reports suggest a role of...” NCT01166035 ↗57“A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small cell Lung Cancer With...” NCT01090011 ↗ “A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor...” NCT00079066 ↗ “Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux)...” NCT01892527 ↗ “Cetuximab (ErbituxTM) is designed to prevent or slow down the growth of cancer cells by blocking proteins inside the cancer cell, called the epidermal growth factor receptor (EGFR).” NCT00543504 ↗ “The purpose of this study is to investigate whether cetuximab (Erbitux®) with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective.” NCT00477711 ↗ “Cetuximab (Erbitux®) is a recombinant chimeric human/mouse Immunoglobulin G monoclonal antibody which binds to EGFR and competitively inhibits the binding of EGFR and other ligands” NCT06599502 ↗ “A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79” NCT00216203 ↗ “The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes” NCT01102231 ↗ “Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.” NCT01794845 ↗ “Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).” NCT01315990 ↗ “Tumor with KRAS mutation will not respond to Erbitux treatment, and mucinous tumors are usually more resistant to any chemotherapy” NCT05289076 ↗ “NT219 Injection Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer” NCT04474470 ↗ “The purpose of this study is to determine the role of cetuximab (Erbitux) with chemotherapy for advanced colorectal carcinoma.” NCT00315185 ↗ “based on 5-fluorouracil, folinic acid, and oxaliplatin (Eloxatin®), with the EGF receptor antibody cetuximab (Erbitux®)” NCT00145314 ↗ “Cetuximab (Erbitux®), a chimeric monoclonal antibody binding to the Epidermal Growth Factor Receptor (EGFR)” NCT03874026 ↗ “Cetuximab or Erbitux is a monoclonal antibody against the EGFR (Epidermal Growth Factor Receptor).” NCT00996567 ↗ “Cetuximab (also known as ERBITUX®) is an epidermal growth factor receptor (EGFR) antagonist” NCT07063212 ↗ “cetuximab (Erbitux®), a monoclonal antibody against epidermal growth factor receptor (EGFR)” NCT00933387 ↗ “Cetuximab (Erbitux; Merck, Germany) 400 mg/m2 will be given as an intravenous (IV) infusion” NCT00384878 ↗ “The drug that is to be given in this study is called Cetuximab (also known as "Erbitux").” NCT00494611 ↗ “Cetuximab (Erbitux®) is an antibody against the epidermal growth factor receptor (EGFR).” NCT00660582 ↗ “Cetuximab® (produced by CinnaGen) compared with Erbitux® (Cetuximab, the reference drug)” NCT03391934 ↗ “induction chemotherapy (capecitabine, oxaliplatin and cetuximab (erbitux))” NCT00353457 ↗ “Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)” NCT02438995 ↗ “control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv）” NCT04835142 ↗ “cetuximab (C225, Erbitux) in combination with carboplatin” PMID 18191993 ↗ Jan 2008 “Patients receive weekly infusions of cetuximab (Erbitux)” PMID 16681848 ↗ May 2006 “Erbitux (cetuximab) is a monoclonal antibody” NCT00353717 ↗ “cetuximab (Erbitux) can shrink lung cancers” NCT00716456 ↗ “Cetuximab (Erbitux): 500 mg/m2 iv gtt, D1” NCT01322178 ↗ “Cetuximab (Erbitux®) and Gemcitabine” NCT00395252 ↗ “HLX05 Vs. Erbitux® (Cetuximab)” NCT06309043 ↗ “Cetuximab Injection [Erbitux]” NCT04984369 ↗ “Cetuximab (Erbitux, C225)” NCT00388427 ↗ “cetuximab (Erbitux®)” NCT00908024 ↗ “Cetuximab( erbitux®)” NCT02020577 ↗ “cetuximab (Erbitux®)” NCT00640471 ↗ “Cetuximab (Erbitux)” NCT07204574 ↗ “Erbitux (Cetuximab)” NCT07381764 ↗ “Erbitux (Cetuximab)” NCT07389265 ↗ “Cetuximab (ERBITUX)” NCT01973868 ↗ “Cetuximab (Erbitux)” NCT06640725 ↗ “cetuximab (Erbitux)” NCT00514943 ↗ “Erbitux (Cetuximab)” NCT01884740 ↗ “Erbitux (Cetuximab)” NCT00044863 ↗ “Cetuximab (Erbitux)” NCT06988852 ↗ “Cetuximab/Erbitux” NCT02741570 ↗ |
| Known as | Erbitux (cetuximab) | “Erbitux (cetuximab)” NCT00931840 ↗1“ERBITUX (cetuximab)” NCT00517829 ↗ |
| Known as | ErbituxÒ | “Cetuximab (ErbituxÒ) (Arm B only) every two weeks:” NCT00552149 ↗ |
| Known as | IMC-C225 | “Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine” NCT00075686 ↗1“IMC-C225” NCT00980239 ↗ |
| Known as | NSC #714692 | “A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer” NCT00104910 ↗1“cetuximab (C225, NSC #714692) in Combination With Carboplatin (NSC #241240)” NCT00086892 ↗ |
| Known as | RPH-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07435324 ↗ |
| Action | Inhibit | “the monoclonal antibody EGFR inhibitor, cetuximab” PMID 16246975 ↗ Oct 2005 |
| Modality | Monoclonal antibody | “We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor...” PMID 16467544 ↗ Feb 2006 |
| Route | Intravenous | “Patients receive maintenance cetuximab IV over 1 hour on day 8.” NCT00004227 ↗ |
| Target | EGFR | “Phase II Study of Cetuximab Anti-Epidermal Growth Factor Receptor (EGFr) Antibody” NCT00004865 ↗ |